WALTHAM, Mass.--(BUSINESS WIRE)--Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, today announced that it has resumed its Phase 2 trial of SJX-653, a novel, potent, and selective neurokinin 3 (NK3) antagonist in development as a non-hormonal once-daily treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes. The Phase 2 trial was paused earlier this year due to COVID-19 and has now been amended and resumed with a streamlined design and integration of remote clinical trial techniques to reduce in-person contact and help safeguard the safety of patients and study personnel during the pandemic.
WALTHAM, Mass.--(BUSINESS WIRE)--Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, today announced that it has resumed its Phase 2 trial of SJX-653, a novel, potent, and selective neurokinin 3 (NK3) antagonist in development as a non-hormonal once-daily treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes. The Phase 2 trial was paused earlier this year due to COVID-19 and has now been amended and resumed with a streamlined design and integration of remote clinical trial techniques to reduce in-person contact and help safeguard the safety of patients and study personnel during the pandemic.
WALTHAM, Mass.--(BUSINESS WIRE)-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, announced today the publication of results from a Phase 1 proof-of-mechanism clinical study of SJX-653 in The Journal of Clinical Endocrinology & Metabolism. SJX-653 is a novel, potent, highly-selective neurokinin 3 (NK3) antagonist in clinical development as a non-hormonal once-daily treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.